Advaxis Inc. (NASDAQ:ADXS) was up 4.8% on Monday . The company traded as high as $14.93 and last traded at $14.86, with a volume of 479,454 shares traded. The stock had previously closed at $14.18.

A number of equities research analysts have weighed in on ADXS shares. Jefferies Group reissued a “buy” rating on shares of Advaxis in a report on Thursday, August 4th. HC Wainwright reissued a “buy” rating and set a $23.00 target price on shares of Advaxis in a report on Friday, August 5th. Barclays PLC boosted their target price on shares of Advaxis from $15.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, August 3rd. Finally, FBR & Co reissued an “outperform” rating and set a $34.00 target price on shares of Advaxis in a report on Tuesday, May 17th. Six research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus target price of $25.80.

The stock’s market cap is $482.90 million. The company’s 50 day moving average price is $10.05 and its 200-day moving average price is $8.54.

In other news, Director Richard J. Berman sold 18,000 shares of the stock in a transaction dated Monday, August 8th. The shares were sold at an average price of $15.21, for a total value of $273,780.00. Following the sale, the director now directly owns 66,430 shares of the company’s stock, valued at $1,010,400.30. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director David Sidransky sold 22,808 shares of the stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $15.01, for a total transaction of $342,348.08. Following the completion of the sale, the director now directly owns 91,759 shares in the company, valued at $1,377,302.59. The disclosure for this sale can be found here.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.